Differential activation of Gi and Gs proteins by E- and I-type prostaglandins in membranes from the human erythroleukaemia cell line, HEL.
The group of prostaglandin (PG) E2- and prostacyclin receptors consists of different subtypes, which exhibit different affinities for prostaglandins and synthetic analogues. PGE2 activities the E-type PG receptor subtypes EP1, EP2 and EP3, whereas the PGE2 analogue, sulprostone, binds only to the EP1 and EP3 receptor subtypes. The stable PGI2 analogues, iloprost and cicaprost, both activate the PGI2 receptor (IP) and iloprost, additionally, bind to the EP1 subtype. Using these subtype-selective PG receptor agonists, we studied the interaction of PG receptor subtypes with Gs and Gi-type heterotrimeric guanine nucleotide-binding proteins (G proteins) in membranes from the human erythroleukaemia cell line, HEL. Sulprostone stimulated high-affinity GTPase in HEL membranes in a pertussis toxin (PTX)-sensitive manner. In contrast, the stimulations induced by PGE2, iloprost and cicaprost were only partially inhibited by PTX. PGE2, sulprostone, iloprost and cicaprost stimulated cholera toxin-catalysed ADP-ribosylation as well as labelling with GTP azidoanilide of membrane proteins comigrating with immunologically identified Gi protein alpha subunits. Furthermore, PGE2, iloprost and cicaprost enhanced GTP azidoanilide-labelling of Gs protein alpha subunits, whereas sulprostone did not. We suggest that in HEL cells (1) EP1 and EP3 receptor subtypes activate G1 proteins, that (2) the EP2 receptor subtype activates Gs proteins and that (3) the IP receptor activates both Gi and Gs proteins.
Schwaner
I
I
Freie Universität Berlin, Institut für Pharmakologie, Germany.
Offermanns
S
S
Spicher
K
K
Seifert
R
R
Schultz
G
G
D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism*; D015232:Dinoprostone / Q000031:analogs & derivatives / Q000494:pharmacology; D011464:Epoprostenol / Q000031:analogs & derivatives / Q000494:pharmacology*; D019204:GTP-Binding Proteins / Q000378:metabolism*; D006801:Humans; D016285:Iloprost / Q000494:pharmacology; D004915:Leukemia, Erythroblastic, Acute / Q000378:metabolism; D011458:Prostaglandins E / Q000494:pharmacology*; D044006:Receptors, Epoprostenol; D011982:Receptors, Prostaglandin / Q000187:drug effects; D018078:Receptors, Prostaglandin E / Q000187:drug effects; D015398:Signal Transduction; D014407:Tumor Cells, Cultured
D011458:Prostaglandins E; D044006:Receptors, Epoprostenol; D011982:Receptors, Prostaglandin; D018078:Receptors, Prostaglandin E; C016767:sulprostone; D011464:Epoprostenol; D019204:GTP-Binding Proteins; D016285:Iloprost; D015232:Dinoprostone; C043867:cicaprost